Tharimmune (NASDAQ:THAR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tharimmune (NASDAQ:THAR) to a hold rating in a report published on Friday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a research note on Saturday, September 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Tharimmune Price Performance

Shares of THAR opened at $2.91 on Friday. The company has a 50-day moving average of $2.98 and a two-hundred day moving average of $1.99. The stock has a market cap of $17.17 million, a price-to-earnings ratio of -0.48 and a beta of 1.41. Tharimmune has a one year low of $0.95 and a one year high of $9.08.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.06).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. XTX Topco Ltd purchased a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,911 shares of the company’s stock, valued at approximately $25,000. XTX Topco Ltd owned 0.31% of Tharimmune as of its most recent SEC filing. Hedge funds and other institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).